HAPILA and Transo-Pharm together at CPHI Frankfurt 2022 - booth 110D20
HAPILA GmbH and Transo-Pharm Handels-GmbH are determined to deepen their relationship and have therefore jointly decided to expand the production capacities at the HAPILA site in Gera, mainly to meet the increasing demand for the active ingredient Estriol Micronized.
Enforcement Report - Week of August 4, 2021
Enforcement Report - Week of June 10, 2020
Enforcement Report - Week of January 15, 2020
Enforcement Report - Week of January 1, 2020
Asclemed USA Inc Receives FDA Warning Letter